EGFR and colorectal cancer: Similarly, treatment of colorectal cancer with anti-EGFR monoclonal antibodies cetuximab or panitumumab is only successful in a subset of patients [290] due to the appearance of Ras mutations and variations in the EGFR extracellular domain, which reduce antibody binding efficiency, initiating relapse [285].